ROYALTY PURCHASE AGREEMENT BY AND BETWEEN APR APPLIED PHARMA RESEARCH S.A. AND SWK FUNDING LLC DATED AS OF DECEMBER 2, 2015Royalty Purchase Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
THIS ROYALTY PURCHASE AGREEMENT entered and made effective as of this 2nd day of December, 2015 (this “Agreement”), by and between APR APPLIED PHARMA RESEARCH S.A., a corporation organized and existing according to the laws of Switzerland (“Seller”), and SWK FUNDING LLC, a Delaware limited liability company (“Purchaser”).
ContractShare Purchase Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
COLLABORATION AGREEMENTCollaboration Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
This COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of November 23, 2021 (the “Effective Date”), by and between InveniAI LLC, a wholly owned subsidiary of [***], a Delaware Incorporated located at 2614 Boston Post Road, Suite 33B, Guilford, CT 06437 (“InveniAI”) and Relief Therapeutics Holding SA, a Switzerland corporation located at Bâtiment F2/F3, Avenue de Sécheron 15, 1202 Genève, Switzerland (“Relief”).
ContractShare Exchange Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED
RELIEF THERAPEUTICS / NEURORX BINDING COLLABORATION AGREEMENTBinding Collaboration Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
This Binding Collaboration Agreement (this “Agreement”), dated as of September 18, 2020 outlines the terms and conditions of the Collaboration (defined below) between Relief Therapeutics Holding Aktiengesellschaft and its wholly owned subsidiary Therametrics Discovery Aktiengesellschaft (collectively, “Relief”), Swiss corporations, and NeuroRx, Inc. (“NeuroRx”), a Delaware corporation (each a “Party” and, collectively, the “Parties”). The Parties hereby acknowledge and agree that the terms set forth in that certain Non-Disclosure Agreement between the Parties, dated as of September 9, 2020, apply to the terms set forth herein.
CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Confidential Share Subscription Facility...Share Subscription Facility Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into on March 19, 2021 (the “Effective Date”) between ACER THERAPEUTICS INC., a Delaware corporation, with its principal place of business at 300 Washington Street, Suite 351, Newton, MA, USA (“Acer”), and RELIEF THERAPEUTICS HOLDING AG, a company organized and existing under the laws of Switzerland and having its registered address at Avenue de Secheron 15, 1202 Geneve, Switzerland (“Relief”). Relief and Acer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment no. 2 to the Master Service Agreement on Order to Cash ServiceMaster Service Agreement on Order to Cash Service • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations
This Amendment N. 2 (hereinafter the “Amendment 2”) to the Master Service Agreement on Order to cash Service with an effective date of 1st September 2018, is made on this July 13th, 2021 (the “Amendment 2 Effective Date”) by and between:
CERTAIN CONFIDENTIAL INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Master Service Agreement on Order to...Master Service Agreement • March 18th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations
WHEREAS, APR is contracting comprehensive logistics and order to cash services for its Products under the terms and conditions set forth in this Agreement.
